In an attempt to build its immunotherapy pipeline, Genentech has agreed to collaborate with clinical stage diagnostics specialist, Adaptive Biotechnologies, to develop next-generation T-cell receptor (TCR) therapies for the treatment of a broad range of cancers. Genentech will leverage Adaptive’s TCR discovery and immune profiling platform, TruTCR™, to develop personalised cancer therapies. Adaptive already has the likes of Pfizer, Amgen and Sanofi validating its technology, but with this deal, gains the expertise of the current oncology leader.